CO6351811A2 - La proteina de tuberculosis rv2386c, composiciones y usos de la misma - Google Patents
La proteina de tuberculosis rv2386c, composiciones y usos de la mismaInfo
- Publication number
- CO6351811A2 CO6351811A2 CO11009237A CO11009237A CO6351811A2 CO 6351811 A2 CO6351811 A2 CO 6351811A2 CO 11009237 A CO11009237 A CO 11009237A CO 11009237 A CO11009237 A CO 11009237A CO 6351811 A2 CO6351811 A2 CO 6351811A2
- Authority
- CO
- Colombia
- Prior art keywords
- rv2386c
- compositions
- same
- tuberculosis protein
- protein sequence
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 4
- 201000008827 tuberculosis Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 101100456232 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) mbtI gene Proteins 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Mycobacteriaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/5695—Mycobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- General Physics & Mathematics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8369908P | 2008-07-25 | 2008-07-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6351811A2 true CO6351811A2 (es) | 2011-12-20 |
Family
ID=41227131
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO11009237A CO6351811A2 (es) | 2008-07-25 | 2011-01-27 | La proteina de tuberculosis rv2386c, composiciones y usos de la misma |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20110206712A1 (enExample) |
| EP (1) | EP2315834B1 (enExample) |
| JP (2) | JP5981138B2 (enExample) |
| KR (1) | KR20110049834A (enExample) |
| CN (2) | CN106866801A (enExample) |
| AU (1) | AU2009273132B2 (enExample) |
| BR (1) | BRPI0916704A2 (enExample) |
| CA (1) | CA2731547C (enExample) |
| CO (1) | CO6351811A2 (enExample) |
| CY (1) | CY1121632T1 (enExample) |
| DK (1) | DK2315834T3 (enExample) |
| EA (1) | EA201100070A1 (enExample) |
| ES (1) | ES2685498T3 (enExample) |
| HR (1) | HRP20181353T1 (enExample) |
| HU (1) | HUE039159T2 (enExample) |
| IL (1) | IL210589A (enExample) |
| LT (1) | LT2315834T (enExample) |
| MX (1) | MX2011000982A (enExample) |
| PL (1) | PL2315834T3 (enExample) |
| PT (1) | PT2315834T (enExample) |
| SI (1) | SI2315834T1 (enExample) |
| UA (1) | UA107329C2 (enExample) |
| WO (1) | WO2010010179A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2428801B1 (en) * | 2006-03-14 | 2014-05-07 | Oregon Health and Science University | Methods for detecting a mycobacterium tuberculosis infection |
| US20110189217A1 (en) * | 2008-06-26 | 2011-08-04 | Barry Michael A | Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance |
| PL2315834T3 (pl) | 2008-07-25 | 2018-12-31 | Glaxosmithkline Biologicals S.A. | Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania |
| WO2010010180A1 (en) * | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A. | Novel compositions and methods |
| GB201116248D0 (en) | 2011-09-20 | 2011-11-02 | Glaxosmithkline Biolog Sa | Liposome production using isopropanol |
| WO2013090897A1 (en) * | 2011-12-15 | 2013-06-20 | The Trustees Of The University Of Pennsylvania | Using adaptive immunity to detect drug resistance |
| CN107478849B (zh) * | 2013-05-31 | 2019-08-20 | 中国医学科学院病原生物学研究所 | 用于结核病诊断和预防的蛋白 |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| EP3180353B1 (en) | 2014-08-15 | 2021-09-22 | Oxford Immunotec Limited | Mycobacterium tuberculosis proteins |
| CN105572352B (zh) * | 2016-02-17 | 2017-07-28 | 遵义医学院附属医院 | 一组结核潜伏感染诊断标志物及其用途 |
| MX2019006728A (es) | 2016-12-07 | 2019-12-02 | Glaxosmithkline Biologicals Sa | Nuevo proceso. |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| DE112018002827T5 (de) | 2017-05-30 | 2020-04-09 | Glaxosmithkline Biologicals S.A. | Neue Verfahren zur Herstellung eines Adjuvans |
| JP2021504424A (ja) | 2017-12-01 | 2021-02-15 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニン精製 |
| CN108950031A (zh) * | 2018-06-29 | 2018-12-07 | 周琳 | 结核分枝杆菌的利福平耐药性诊断标志物及其应用 |
| CN109234414B (zh) * | 2018-06-29 | 2022-05-17 | 周琳 | 结核分枝杆菌的对氨基水杨酸耐药性诊断标志物及其应用 |
| CN108866213A (zh) * | 2018-06-29 | 2018-11-23 | 周琳 | 结核分枝杆菌利福平耐药性诊断标志物及其应用 |
| US20220235095A1 (en) | 2019-06-05 | 2022-07-28 | Glaxosmithkline Biologicals Sa | Saponin purification |
| EP3983011A1 (en) * | 2019-06-14 | 2022-04-20 | Statens Serum Institut | Fusion proteins for tuberculosis vaccines |
| CN112457410B (zh) * | 2020-11-05 | 2023-04-07 | 迈克生物股份有限公司 | 用于结核分枝杆菌感染检测的抗原组合物 |
| DE202022102137U1 (de) | 2022-04-21 | 2022-04-28 | Damayanthi Dalu | Eine neue Zusammensetzung zur Behandlung von Tuberkulose |
| CN115073612B (zh) * | 2022-06-22 | 2024-09-27 | 宁夏大学 | 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途 |
| CN115725607B (zh) * | 2022-07-14 | 2023-11-28 | 山东第一医科大学附属省立医院(山东省立医院) | 一种鼻疽诺卡菌的致病靶基因及其应用 |
| CN120058854A (zh) * | 2025-03-05 | 2025-05-30 | 北京知筹科技有限公司 | 一种调节低密度脂蛋白受体相关蛋白（lrp）的多肽及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA40597C2 (uk) | 1992-06-25 | 2001-08-15 | Смітклайн Бічем Байолоджікалс С.А. | Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів |
| US6458366B1 (en) | 1995-09-01 | 2002-10-01 | Corixa Corporation | Compounds and methods for diagnosis of tuberculosis |
| US6592877B1 (en) | 1995-09-01 | 2003-07-15 | Corixa Corporation | Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| US6613881B1 (en) | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
| IL138809A0 (en) | 1998-04-07 | 2001-10-31 | Corixa Corp | Fusion proteins of mycobacterium tuberculosis antigens and pharmaceutical compositions containing the same |
| AU2001241738A1 (en) | 2000-02-25 | 2001-09-03 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| WO2001098460A2 (en) | 2000-06-20 | 2001-12-27 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US20040121322A9 (en) | 2001-02-22 | 2004-06-24 | Cole Stewart T. | Comparative mycobacterial genomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| AU2003213118A1 (en) | 2002-02-15 | 2003-09-09 | Corixa Corporation | Fusion proteins of mycobacterium tuberculosis |
| US20030236393A1 (en) | 2002-03-22 | 2003-12-25 | United States Of America Dept Of Vetrans Affairs | Virulence genes of M. marinum and M. tuberculosis |
| KR101178776B1 (ko) | 2004-02-06 | 2012-09-07 | 카운슬 오브 사이언티픽 앤드 인더스트리얼 리서치 | 치료학적 잠재성을 가진 어드헤신 및 어드헤신계 단백질을 동정하기 위한 컴퓨터 장치 |
| SI2426141T1 (sl) * | 2005-04-29 | 2015-01-30 | Glaxosmithkline Biologicals S.A. | Postopek za preprečevanje ali zdravljenje infekcije z M tuberculosis |
| WO2008007942A1 (en) | 2006-07-10 | 2008-01-17 | Het Nederlands Kanker Instituut | Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof |
| CN103550764A (zh) | 2007-03-02 | 2014-02-05 | 葛兰素史密丝克莱恩生物有限公司 | 疫苗组合物及其在刺激免疫反应中的用途 |
| LT2315773T (lt) | 2008-07-25 | 2016-11-10 | Glaxosmithkline Biologicals S.A. | Polipeptidai, polinukleotidai ir kompozicijos, skirti naudoti latentinės tuberkuliozės gydymui |
| WO2010010180A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A. | Novel compositions and methods |
| WO2010010178A1 (en) | 2008-07-25 | 2010-01-28 | Glaxosmithkline Biologicals S.A | The tuberculosis rv2707c protein, compositions and uses thereof |
| PL2315834T3 (pl) | 2008-07-25 | 2018-12-31 | Glaxosmithkline Biologicals S.A. | Białko rv2386c związane z gruźlicą, jego kompozycje i zastosowania |
| DK2421557T3 (en) | 2009-04-24 | 2019-03-25 | Statens Seruminstitut | TB TUBERCULOSE VACCINE FOR PREVENTION PREVENTION |
| WO2010132112A2 (en) | 2009-05-14 | 2010-11-18 | Wisconsin Alumni Research Foundation | Immunogenic compositions against tuberculosis |
| AU2011209399B2 (en) | 2010-01-27 | 2014-04-10 | Glaxo Group Limited | Modified tuberculosis antigens |
-
2009
- 2009-07-24 PL PL09781057T patent/PL2315834T3/pl unknown
- 2009-07-24 EP EP09781057.6A patent/EP2315834B1/en active Active
- 2009-07-24 BR BRPI0916704-8A patent/BRPI0916704A2/pt not_active IP Right Cessation
- 2009-07-24 EA EA201100070A patent/EA201100070A1/ru unknown
- 2009-07-24 CN CN201710068231.XA patent/CN106866801A/zh active Pending
- 2009-07-24 AU AU2009273132A patent/AU2009273132B2/en not_active Ceased
- 2009-07-24 PT PT97810576T patent/PT2315834T/pt unknown
- 2009-07-24 CA CA2731547A patent/CA2731547C/en active Active
- 2009-07-24 CN CN200980138405.9A patent/CN102165064B/zh active Active
- 2009-07-24 ES ES09781057.6T patent/ES2685498T3/es active Active
- 2009-07-24 LT LTEP09781057.6T patent/LT2315834T/lt unknown
- 2009-07-24 HR HRP20181353TT patent/HRP20181353T1/hr unknown
- 2009-07-24 KR KR1020117004639A patent/KR20110049834A/ko not_active Ceased
- 2009-07-24 UA UAA201100300A patent/UA107329C2/uk unknown
- 2009-07-24 US US13/055,787 patent/US20110206712A1/en not_active Abandoned
- 2009-07-24 MX MX2011000982A patent/MX2011000982A/es active IP Right Grant
- 2009-07-24 SI SI200931869T patent/SI2315834T1/sl unknown
- 2009-07-24 JP JP2011519186A patent/JP5981138B2/ja active Active
- 2009-07-24 HU HUE09781057A patent/HUE039159T2/hu unknown
- 2009-07-24 DK DK09781057.6T patent/DK2315834T3/en active
- 2009-07-24 WO PCT/EP2009/059585 patent/WO2010010179A1/en not_active Ceased
-
2011
- 2011-01-12 IL IL210589A patent/IL210589A/en not_active IP Right Cessation
- 2011-01-27 CO CO11009237A patent/CO6351811A2/es not_active Application Discontinuation
-
2013
- 2013-06-27 US US13/929,232 patent/US20140086948A1/en not_active Abandoned
-
2014
- 2014-05-21 US US14/283,727 patent/US9480735B2/en active Active
-
2015
- 2015-07-03 JP JP2015134587A patent/JP6104326B2/ja not_active Expired - Fee Related
-
2016
- 2016-09-15 US US15/266,220 patent/US10286053B2/en active Active
-
2018
- 2018-08-24 CY CY20181100883T patent/CY1121632T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6351811A2 (es) | La proteina de tuberculosis rv2386c, composiciones y usos de la misma | |
| CO6400198A2 (es) | Composiciones y metodos novedosos | |
| CO6341637A2 (es) | \\\\\\\"composiciones y metodos novedosos\\\\\\\" | |
| CR11580A (es) | Metodos y composiciones que utilizan polipeptidos de fusion de klotho-fgf | |
| CO2020001872A2 (es) | Preparación de exosomas terapéuticos mediante el uso de proteínas de membrana | |
| AR125326A2 (es) | Composiciones de neisseria meningitidis y métodos de las mismas | |
| CL2010001426A1 (es) | Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas. | |
| PE20142451A1 (es) | Composiciones de conjugados de xten y metodos para realizar las mismas | |
| EA200802170A1 (ru) | Лиофилизированная композиция терапевтического пептидного антитела | |
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| CL2010001569A1 (es) | Pestivirus atenuado mediante la mutacion conjunta de las proteinas e erns y n pro.composicion inmunogenica y vacuna que lo comprende, metodo para atenuar pestivirus basado en la supresion de la dimerizacion de la proteina e rns y la ianactivacion de la proteina n pro. | |
| ECSP088440A (es) | Imidazopirazinas como inhibidores de proteinquinasa | |
| BRPI0508421A (pt) | sistemas de transporte biológico de múltiplos componentes | |
| EA201171494A1 (ru) | Миметики белка smac | |
| GT200900163A (es) | Nuevos compuestos y sus efectos sobre el conductismo de la alimentacion. | |
| CR11795A (es) | Inmunoglobulinas con dominio variable dual y usos de las mismas | |
| CL2008000910A1 (es) | Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide. | |
| MX2016003530A (es) | Proteina de fusion. | |
| ECSP10010211A (es) | Composición | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| CL2009001083A1 (es) | Variantes de receptores de la proteina c3 de complemento (crig), molecula quimerica y composicion farmaceutica que las comprende; uso de las variantes para preparar un medicamento para prevenir o tratar una enfermedad asociada al complemento, tal como una enfermedad inflamatoria o autoinmune. | |
| AR104952A1 (es) | Bioconjugados y usos de los mismos | |
| UA107788C2 (en) | A fusion protein of m. tuberculosis | |
| CL2011000646A1 (es) | Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; composicion farmaceutica que los comprende; util en el tratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007). | |
| CL2008003257A1 (es) | Vacuna multicomponente para la enfermedad de chagas que comprende una porcion inmunogenica conformada por uno o mas polipeptidos recombinantes o sinteticos o fragmentos, y uno o mas polinucleotidos que comprenden a las regiones que codifican uno o mas polipeptidos inmunogenicos; vacuna monocomponente; y composicion farmaceutica. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |